Search
for
Sort by
Research 31–60 of 342
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms
- Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: Current Evidence and Potential Mechanisms
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
- Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
- INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
- GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
- EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Abstracts from the 2024 WDS Forum - virtual option
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Ann Robinson’s research reviews —12 May 2022
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches
- Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment—A Single Center Case Series
- Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha
- Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
- Metabolic syndrome — a new definition and management guidelines
- Farmácia Avenida Brasil, Porto
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study